Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Illness, Influenza, SARS-CoV-2 test
Clinical narrative: My wife tested positive for Covid-19 in January 2022, after she got the 1st booster dose of Moderna, because the Ocrevus had knocked out the T cells.; She was sick  with flu symptoms for about 3 weeks.; She was sick  with flu symptoms for about 3 weeks.; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (My wife tested positive for Covid-19 in January 2022, after she got the 1st booster dose of Moderna, because the Ocrevus had knocked out the T cells.), INFLUENZA (She was sick  with flu symptoms for about 3 weeks.) and ILLNESS (She was sick  with flu symptoms for about 3 weeks.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Multiple sclerosis. Concomitant products included OCRELIZUMAB (OCREVUS) for Multiple sclerosis.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In January 2022, the patient experienced COVID-19 (My wife tested positive for Covid-19 in January 2022, after she got the 1st booster dose of Moderna, because the Ocrevus had knocked out the T cells.). On an unknown date, the patient experienced INFLUENZA (She was sick  with flu symptoms for about 3 weeks.) and ILLNESS (She was sick  with flu symptoms for about 3 weeks.). At the time of the report, COVID-19 (My wife tested positive for Covid-19 in January 2022, after she got the 1st booster dose of Moderna, because the Ocrevus had knocked out the T cells.), INFLUENZA (She was sick  with flu symptoms for about 3 weeks.) and ILLNESS (She was sick  with flu symptoms for about 3 weeks.) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2022, SARS-CoV-2 test: positive (Positive) Positive. In 2022, SARS-CoV-2 test: negative (Negative) Negative after 3 weeks..         Ocrevus treatment is every 6 months, which knocks out the T cells. Patient did seek medical care for adverse event. The Ocrevus wipes out the T cells, which is how the Moderna Covid-19 vaccine works to boost the immune system against Covid, then that left her without protection from Covid.  No treatment medication was provided. Company comment- This spontaneous case concerns a female patient of unknown age with relevant medical history of Multiple sclerosis and taking immunosuppressive drug Ocrelizumab for Multiple sclerosis who experienced the unexpected, non-serious adverse event of special interest COVID-19 (with a positive SARS-CoV-2 test) after her first booster dose of mRNA-1273 Vaccine. Details of primary doses of covid 19 vaccines were not reported. Use of Ocrelizumab is a confounder for the event. The event had resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a female patient of unknown age with relevant medical history of Multiple sclerosis and taking immunosuppressive drug Ocrelizumab for Multiple sclerosis who experienced the unexpected, non-serious adverse event of special interest COVID-19 (with a positive SARS-CoV-2 test) after her first booster dose of mRNA-1273 Vaccine. Details of primary doses of covid 19 vaccines were not reported. Use of Ocrelizumab is a confounder for the event. The event had resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.